DUBLIN , Oct. 11, 2021 /PRNewswire/ -- The "Biomaterials Market - A Global and Regional Analysis: Focus on Applications, Product Types, and Countries - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The global biomaterials market was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031.
The major categories product by type includes metal-based biomaterials, polymer-based biomaterials, ceramic-based biomaterials, natural-based biomaterials, inorganic glass-based biomaterials, radiopaque biomaterials, regenerative biomaterials, hybrid biomaterial combinations.
Moreover, the major applications include cardiovascular, orthopedic, ophthalmology, dental, wound healing, plastic surgery, neurological/central nervous system (CNS), tissue engineering, and others.
The biomaterials market is driven by a number of factors such as superior properties of biomaterials, increasing funds/aids by the government for research purposes, increasing wound healing therapies & plastic surgeries, increasing aging/geriatric population, rise in prevalence of cardiovascular diseases, increasing awareness of regenerative medicine, increasing orthopedic disorders, and growing demand for implantable devices.
However, biocompatibility issues, stringent safety regulations, and limitations of biomaterial-based products are hampering the growth of the biomaterials market. Increasing obesity, the introduction of biomaterials in cancer research, and increasing patient awareness and improved lifestyle in growing economies such as India , China , and South Korea are expected to create opportunities in the biomaterials market.
Among different biomaterials applications, cardiovascular dominates the market and is expected to be the largest application during the forecast period.
The growing use of biomaterials in the cardiovascular application segment is majorly subjected to its biocompatibility as biomaterials come in contact with blood, vascular endothelial cells, fibroblasts, and myocardium, as well as a number of other cells and a cellular matrix material.
Biomaterials that are used in the cardiovascular system include materials such as metals and polymers. The use of biomaterials in the cardiovascular system can be classified as temporary internal, temporary external, and permanent internal devices.
Among different biomaterials product type metal-based biomaterials dominates the market and is expected to be the largest product type during the forecast period. The dominance of metal-based biomaterials is attributed to wide use in the applications of biomaterials such as cardiovascular, orthopedic, ophthalmology, dental.
From simple wires, rods, pins, screws to fracture fixation plates and total joint prostheses (artificial joints) for hips, knees, shoulders, and ankles, metals are used in all applications, including maxillofacial surgery, cardiovascular surgery, and dental materials, etc. The metal-based biomaterials include stainless steel, commercially pure titanium and titanium alloys, cobalt and chromium alloys, gold, silver, magnesium, and nitinol.
The demand for biomaterials varies according to various regions. The biomaterials market holds a prominent share in various countries of North America , Asia-Pacific and Japan , Europe , the U.K., China , and Rest-of-the-World, among which North America is expected to be the largest region for the global biomaterials market during the forecast period.
Industrial advancements, extensive investments for dedicated R&D facilities, and the development of different application products that require biomaterials are some of the major drivers that are currently propelling the growth of the North America biomaterials market. Additionally, due to the wide-scale production of biomaterials as well as technological advancements pertaining to the technology, the global market for biomaterials is expected to grow at a steady rate.
Key Questions Answered in the Report
What are the key drivers and challenges in the global biomaterials market?
How does the supply chain function in the global biomaterials market?
Which product type is expected to witness the maximum demand growth in the global biomaterials market during the period 2021-2031?
Which are the key application areas for which biomaterials may experience high demand during the forecast period 2021-2031?
Which are the key suppliers of biomaterials in different countries and regions?
How is the industry expected to evolve during the forecast period 2021-2031?
What are the key offerings of the prominent manufacturers in the global biomaterials market?
Which regions and countries are leading in terms of consumption of biomaterials, and which of them are expected to witness high demand growth from 2021 to 2031?
What are the key consumer attributes in various countries in the global biomaterials market?
Which are the major patents filed in the biomaterials space?
What are the key developmental strategies implemented by the key players to sustain the competitive market?
What is the competitive strength of the key players in the global biomaterials market based on their recent developments, product offerings, and regional presence?
Who are the key players (along with their detailed analysis and profiles, including their company snapshots, key products and services, and strength and weakness analysis) in the market?
Increasing Funds/Aids by Government for Research Purposes
Increasing Plastic Surgery and Wound Healing Therapies
Rise in Prevalence of Cardiovascular Diseases
Growing Demand for Implantable Devices
Increasing Awareness of Regenerative Medicine
Biocompatibility Issues and Safety and Stringent Regulations
Patient Awareness and Improved Lifestyle in Emerging Economies
Introduction of Biomaterials in Cancer Research
Wright Medical Group N.V.
For more information about this report visit https://www.researchandmarkets.com/r/sevp8i
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-biomaterials-markets-report-2021-focus-on-cardiovascular-orthopedic-ophthalmology-dental-wound-healing-plastic-surgery-neurologicalcns--tissue-engineering-301397111.html
Estate planning can be complicated. You often need the services of a professional. Preparing a will is only one part of the estate planning process. When you are preparing your will, you need to decide whether or not a no-contest … Continue reading → The post What Is a No-Contest Clause in a Will? appeared first on SmartAsset Blog.
EV stocks are being dumped as a group today, even with these three names reporting good news recently.
Wood believes we're still in a strong bull market. Take advantage.
More than 90 large-cap stocks are down at least 20% from their 2021 highs, but analysts love many of them, including JD.com, PayPal and Disney.
Yahoo Finance Live's Jared Blikre examines the latest market action, in addition to reporting on Biogen undergoing acquisition negotiations by Samsung
Losing money in the S&P 500 is never fun. But it stings all the more when everyone else is making tons on their stocks.
A cosmetics and skin care products company founded by married Taiwanese actors Zhang Ting and Lin Ruiyang has had assets worth 600 million yuan (US$94 million) frozen due to an investigation by China's market regulator over an alleged pyramid scheme. The market regulator in Shijiazhuang, the capital of northern China's Hebei province, said it had received several reports about a suspected pyramid scheme involving Shanghai Dowell Trading, according to a letter widely circulated on Chinese social
The year is winding down, and it’s time for Wall Street’s analysts to flag their top picks for the coming year. It’s a time-honored tradition, in most walks of life, to take a sometimes tongue-in-cheek look at what lies ahead, and to start giving advice on the say-so of a metaphorical crystal ball. Analysts have been analyzing each stock carefully, looking at its past and current performance, its trends on a variety of time frames, management’s plans – the analysts take everything into account.
Buffett is taking profits off the table. It might be time to do the opposite.
Nvidia (NASDAQ: NVDA) stock dropped in Wednesday trading and is down 2% as of 11 a.m. ET, and bad news out of China may be the reason. This morning, Samsung announced that "due to the ongoing COVID-19 situation, we have decided to temporarily adjust operations at our manufacturing facilities in Xian, China." What does a Samsung plant in China have to do with a sliding stock price for Nvidia?
What happened Shares of Novavax (NASDAQ: NVAX) were slipping 2.6% lower as of 11:35 a.m. ET on Wednesday. The company didn't report any new developments since yesterday's announcement that India had granted Emergency Use Authorization (EUA) to COVID-19 vaccine NVX-CoV2373.
Let’s talk about penny stocks. These are equities that trade for less than $5 per share, the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among the penny stocks, and set themselves up for outsized gains. The opportunity is linked to a simple question: Why is the company’s stock priced so low? If the answer is mainly benig
These stocks are trading near their 52-week lows but have tremendous long-term growth opportunities.
The rally in Victoria's Secret may just be getting started, contends JP Morgan retail analyst Matt Boss.
Get aboard the Tesla stock train, argues Dan Ives at Wedbush.
What happened Shares of Ocugen (NASDAQ: OCGN) were falling 5.1% as of 12:03 p.m. ET on Wednesday. The company hasn't made any announcements this week. Its stock appears to simply be continuing a slide that began in early November.
Biogen, which owns nearly half of a Samsung unit, shares surged Wednesday. A South Korean newspaper reported that Samsung wants to buy Biogen for as much as $42 billion.
For the second day in a row, shares of electric truck start-up Rivian (NASDAQ: RIVN) are rolling downhill. Down 5.4% as of 11:40 a.m. ET on Wednesday, the speed of Rivian stock's slide seems to be accelerating since yesterday. In a midday story yesterday, the electric cars news site reported on an email sent out by Rivian CEO RJ Scaringe to Rivian customers who had ordered "Adventure and Explore Package" models of R1T electric pickup trucks and R1T electric SUVs.
The need of a robust charging infrastructure to support the growth of electric vehicles (EVs) is undisputed. What isn't as clear is which players will be instrumental in developing this infrastructure and, more importantly, whether can they do this profitably. Let's discuss which of the two top EV charging stocks, ChargePoint (NYSE: CHPT) and Blink Charging (NASDAQ: BLNK), is a better buy right now.
(Bloomberg) -- Mukesh Ambani, Asia’s richest man, wants to expedite Reliance Industries Ltd.’s leadership transition and sees his $217 billion empire scaling new heights under his three children.Most Read from BloombergGhislaine Maxwell Found Guilty in Win for Epstein VictimsApple Aims to Prevent Defections to Meta With Rare $180,000 Bonuses for Top TalentMercedes Swept Up in China Internet Furor Over Model’s EyesThe Senator Who Could Rescue Biden’s AgendaCovid With Omicron Isn’t ‘Same Disease,’